Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.09.001
Julio Roberto Amador , Carolina Becerra-Arias , Wilmer Gerardo Rojas-Zuleta , Juan Raul Castro-Ayarza , Manuel Franco , Mario Barbosa-Rengifo , Jorge Donado-Gómez , Natalia Duque-Zapata
<div><h3>Introduction</h3><div>Psoriasis is a chronic inflammatory disease characterized by scaly erythematous plaques, systemic inflammation, and an elevated cardiovascular risk. Due to its complexity in treatment and the frequent occurrence of comorbidities, characterizing patients diagnosed with psoriasis enrolled in care programmes becomes paramount for enhancing health outcomes.</div></div><div><h3>Objective</h3><div>To provide a comprehensive description of the sociodemographic, clinical features, and outcomes of a cohort of patients diagnosed with psoriasis in a multicentre outpatient healthcare institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>A cohort study was conducted involving patients diagnosed with psoriasis. Inclusion criteria required a minimum follow-up duration of three months. Quantitative variables were summarized using the median and interquartile range, while qualitative variables were presented with measures of frequency and 95% confidence interval. Changes in the final values of PASI, DLQI, NAPSI, and BSA from baselines were assessed through percentage comparisons, analysed using chi-square test.</div></div><div><h3>Results</h3><div>A total of 1155 patients were included, with a median age of 53 years and the majority were men (58%). Plaque psoriasis was the predominant type, observed in 78.7%. Psoriatic arthritis was diagnosed in 18.9%. The most prevalent comorbidity was hypertension, identified in 23.0% (95% CI 20.6 to 25.6%), followed by diabetes at 12.5% (95% CI 10.6 to 14.5%) and cardiovascular disease at 10.6%. A significant proportion of patients were classified as overweight and obese, 43.9% (n<!--> <!-->=<!--> <!-->479) and 20.9% (n<!--> <!-->=<!--> <!-->228), respectively. Regarding treatment modalities, the majority received biological therapies (39%), followed by systemic therapy (22.2%), and topical therapy (17.5%).</div><div>During the follow-up period, a considerable percentage of patients experienced some decrease in disease activity. A PASI75 response was achieved by 28.5% (95% CI 25.4% to 31.8%), and PASI90% was achieved by 18% (95% CI 15.4% to 20.9%). A bivariate analysis based on Body Mass Index showed a lower response in patients with overweight or obesity, thought these differences were not statistically significant (p<!--> <!-->=<!--> <!-->.937). Notably, a higher percentage of patients with no response were observed among those with hypertension (62.9% p<!--> <!-->=<!--> <!-->.123), diabetes mellitus (64.7% p<!--> <!-->=<!--> <!-->.393), cardiovascular disease (51.5% p<<!--> <!-->.001), and chronic kidney disease (55.6% p<!--> <!-->=<!--> <!-->.014) when compared with patients who achieved therapeutic goals.</div></div><div><h3>Conclusions</h3><div>We present the largest psoriasis cohort in Colombia. A majority of our patients showed improvement in disease activity based on clinimetric measures. Nevertheless, the presence of comorbidities significantly reduces the likel
银屑病是一种慢性炎症性疾病，以鳞状红斑斑块、全身炎症和心血管风险升高为特征。由于其治疗的复杂性和合并症的频繁发生，诊断为牛皮癣的患者的特征登记在护理方案中成为提高健康结果的重要因素。目的：对哥伦比亚一家多中心门诊医疗机构诊断为牛皮癣的一组患者的社会人口学、临床特征和结果进行全面描述。材料与方法对诊断为牛皮癣的患者进行了一项队列研究。纳入标准要求至少随访3个月。定量变量用中位数和四分位数范围来概括，而定性变量用频率和95%置信区间来表示。PASI、DLQI、NAPSI和BSA最终值与基线的变化通过百分比比较进行评估，使用卡方检验进行分析。结果共纳入1155例患者，中位年龄53岁，男性居多（58%）。斑块型银屑病为主要类型，占78.7%。诊断为银屑病关节炎的占18.9%。最常见的合并症是高血压，占23.0% (95% CI 20.6 - 25.6%)，其次是糖尿病，占12.5% (95% CI 10.6 - 14.5%)，心血管疾病占10.6%。超重和肥胖患者占比显著，分别为43.9% （n = 479）和20.9% （n = 228）。在治疗方式方面，大多数接受生物治疗（39%），其次是全身治疗（22.2%）和局部治疗（17.5%）。在随访期间，相当一部分患者的疾病活动有所减少。PASI75缓解率为28.5% (95% CI 25.4%至31.8%)，PASI90%缓解率为18% （95% CI 15.4%至20.9%）。基于身体质量指数的双变量分析显示，超重或肥胖患者的反应较低，尽管这些差异没有统计学意义（p = .937）。值得注意的是，与达到治疗目标的患者相比，高血压（62.9% p = .123）、糖尿病（64.7% p = .393）、心血管疾病（51.5% p = .001）和慢性肾脏疾病（55.6% p = .014）患者无反应的比例更高。结论：我们提出了哥伦比亚最大的牛皮癣队列。根据临床测量，我们的大多数患者表现出疾病活动度的改善。然而，合并症的存在显著降低了获得治疗反应的可能性。多学科方法结合严密的随访可确保更好的结果，突出了实施现实世界的多学科护理规划的重要性。
{"title":"Clinical characteristic and outcomes of psoriasis patients in a multicentre outpatient healthcare institution in Colombia","authors":"Julio Roberto Amador , Carolina Becerra-Arias , Wilmer Gerardo Rojas-Zuleta , Juan Raul Castro-Ayarza , Manuel Franco , Mario Barbosa-Rengifo , Jorge Donado-Gómez , Natalia Duque-Zapata","doi":"10.1016/j.rcreue.2025.09.001","DOIUrl":"10.1016/j.rcreue.2025.09.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Psoriasis is a chronic inflammatory disease characterized by scaly erythematous plaques, systemic inflammation, and an elevated cardiovascular risk. Due to its complexity in treatment and the frequent occurrence of comorbidities, characterizing patients diagnosed with psoriasis enrolled in care programmes becomes paramount for enhancing health outcomes.</div></div><div><h3>Objective</h3><div>To provide a comprehensive description of the sociodemographic, clinical features, and outcomes of a cohort of patients diagnosed with psoriasis in a multicentre outpatient healthcare institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>A cohort study was conducted involving patients diagnosed with psoriasis. Inclusion criteria required a minimum follow-up duration of three months. Quantitative variables were summarized using the median and interquartile range, while qualitative variables were presented with measures of frequency and 95% confidence interval. Changes in the final values of PASI, DLQI, NAPSI, and BSA from baselines were assessed through percentage comparisons, analysed using chi-square test.</div></div><div><h3>Results</h3><div>A total of 1155 patients were included, with a median age of 53 years and the majority were men (58%). Plaque psoriasis was the predominant type, observed in 78.7%. Psoriatic arthritis was diagnosed in 18.9%. The most prevalent comorbidity was hypertension, identified in 23.0% (95% CI 20.6 to 25.6%), followed by diabetes at 12.5% (95% CI 10.6 to 14.5%) and cardiovascular disease at 10.6%. A significant proportion of patients were classified as overweight and obese, 43.9% (n<!--> <!-->=<!--> <!-->479) and 20.9% (n<!--> <!-->=<!--> <!-->228), respectively. Regarding treatment modalities, the majority received biological therapies (39%), followed by systemic therapy (22.2%), and topical therapy (17.5%).</div><div>During the follow-up period, a considerable percentage of patients experienced some decrease in disease activity. A PASI75 response was achieved by 28.5% (95% CI 25.4% to 31.8%), and PASI90% was achieved by 18% (95% CI 15.4% to 20.9%). A bivariate analysis based on Body Mass Index showed a lower response in patients with overweight or obesity, thought these differences were not statistically significant (p<!--> <!-->=<!--> <!-->.937). Notably, a higher percentage of patients with no response were observed among those with hypertension (62.9% p<!--> <!-->=<!--> <!-->.123), diabetes mellitus (64.7% p<!--> <!-->=<!--> <!-->.393), cardiovascular disease (51.5% p<<!--> <!-->.001), and chronic kidney disease (55.6% p<!--> <!-->=<!--> <!-->.014) when compared with patients who achieved therapeutic goals.</div></div><div><h3>Conclusions</h3><div>We present the largest psoriasis cohort in Colombia. A majority of our patients showed improvement in disease activity based on clinimetric measures. Nevertheless, the presence of comorbidities significantly reduces the likel","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 301-308"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.08.002
Bibiana Andrea Pinzón Valderrama
{"title":"Towards a more accurate quantification of pulmonary fibrosis in scleroderma: Reflections on Goh's method and its geometric correction","authors":"Bibiana Andrea Pinzón Valderrama","doi":"10.1016/j.rcreue.2025.08.002","DOIUrl":"10.1016/j.rcreue.2025.08.002","url":null,"abstract":"","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 299-300"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.09.002
Emine Öztürk , Dilara Bulut Gökten , Rıdvan Mercan , Savaş Güzel
Introduction/Objective
In our study, we investigated the role of Parkinsonism-associated protein 7 (PARK-7), known as DJ-1, which is involved in several pathways that counteract oxidative stress. This stress is thought to contribute to the development of fibrosis and vascular damage in patients with systemic sclerosis (SSc). Our study aims to investigate the correlation between PARK-7 levels, laboratory and clinical findings related to SSc and treatment regimens.
Materials and methods
In our study, we included fifty patients aged 18 years and older diagnosed with SSc and thirty healthy individuals without any systemic, malignant, or autoimmune diseases as a control group. We collected demographic data, clinical manifestations, laboratory and radiological findings, pulmonary function test (PFT), and echocardiography reports, information on comorbidities and prescribed medications from medical records, hospital database analysis, and direct patient interviews. Disease activity was quantified and documented using activity scoring systems developed by the European Scleroderma Study Group (EScSG) and the United Kingdom's (UK) Functional Activity Scoring. PARK-7 levels in venous blood samples from participating patients were quantified by Enzyme-Linked Immunosorbent Assay (ELISA).
Results
The PARK-7 level was 21.26 ± 15.83 in the patient group and 16.11 ± 11.83 in the control group. There was no significant difference in PARK-7 levels between the patient and control groups (p = .22). In terms of disease subtypes, PARK-7 levels were 21.35 ± 18.36 in the limited form, 23.18 ± 13.83 in the diffuse form. No statistically significant differences were observed between PARK-7 levels, the control group, and the different disease forms (p > .05). In patients classified as having active disease according to the EScSG scoring system, the PARK-7 level was 25.69 ± 18.10 compared to 16.00 ± 10.91 in the inactive group. No significant correlation was found between the presence of high-resolution computed tomography (HRCT) findings, other systemic involvement, and PARK-7 levels.
Conclusions
Over the past decade, numerous reports have highlighted the therapeutic potential of PARK-7 and its related molecules for the treatment of various diseases. Whether PARK-7 can be effectively used in the treatment of SSc remains unclear due to the cross-sectional design of our study. We believe that a study measuring PARK-7 levels in patients newly diagnosed or in the early stages of SSc, followed by randomised and prospective follow-up of clinical outcomes with and without treatment, could significantly improve our understanding of the role of PARK-7 in the pathogenesis of SSc and its potential applicability in
{"title":"Retrospective evaluation of PARK-7 expression dynamics in systemic sclerosis","authors":"Emine Öztürk , Dilara Bulut Gökten , Rıdvan Mercan , Savaş Güzel","doi":"10.1016/j.rcreue.2025.09.002","DOIUrl":"10.1016/j.rcreue.2025.09.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>In our study, we investigated the role of Parkinsonism-associated protein 7 (PARK-7), known as DJ-1, which is involved in several pathways that counteract oxidative stress. This stress is thought to contribute to the development of fibrosis and vascular damage in patients with systemic sclerosis (SSc). Our study aims to investigate the correlation between PARK-7 levels, laboratory and clinical findings related to SSc and treatment regimens.</div></div><div><h3>Materials and methods</h3><div>In our study, we included fifty patients aged 18 years and older diagnosed with SSc and thirty healthy individuals without any systemic, malignant, or autoimmune diseases as a control group. We collected demographic data, clinical manifestations, laboratory and radiological findings, pulmonary function test (PFT), and echocardiography reports, information on comorbidities and prescribed medications from medical records, hospital database analysis, and direct patient interviews. Disease activity was quantified and documented using activity scoring systems developed by the European Scleroderma Study Group (EScSG) and the United Kingdom's (UK) Functional Activity Scoring. PARK-7 levels in venous blood samples from participating patients were quantified by Enzyme-Linked Immunosorbent Assay (ELISA).</div></div><div><h3>Results</h3><div>The PARK-7 level was 21.26<!--> <!-->±<!--> <!-->15.83 in the patient group and 16.11<!--> <!-->±<!--> <!-->11.83 in the control group. There was no significant difference in PARK-7 levels between the patient and control groups (<em>p</em> <!-->=<!--> <!-->.22). In terms of disease subtypes, PARK-7 levels were 21.35<!--> <!-->±<!--> <!-->18.36 in the limited form, 23.18<!--> <!-->±<!--> <!-->13.83 in the diffuse form. No statistically significant differences were observed between PARK-7 levels, the control group, and the different disease forms (<em>p</em> <!-->><!--> <!-->.05). In patients classified as having active disease according to the EScSG scoring system, the PARK-7 level was 25.69<!--> <!-->±<!--> <!-->18.10 compared to 16.00<!--> <!-->±<!--> <!-->10.91 in the inactive group. No significant correlation was found between the presence of high-resolution computed tomography (HRCT) findings, other systemic involvement, and PARK-7 levels.</div></div><div><h3>Conclusions</h3><div>Over the past decade, numerous reports have highlighted the therapeutic potential of PARK-7 and its related molecules for the treatment of various diseases. Whether PARK-7 can be effectively used in the treatment of SSc remains unclear due to the cross-sectional design of our study. We believe that a study measuring PARK-7 levels in patients newly diagnosed or in the early stages of SSc, followed by randomised and prospective follow-up of clinical outcomes with and without treatment, could significantly improve our understanding of the role of PARK-7 in the pathogenesis of SSc and its potential applicability in","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 309-314"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.09.006
Miguel Ángel Villarreal-Alarcón , Jorge Antonio Esquivel-Valerio , David Vega-Morales , Jorge Armando Hermosillo-Villafranca , Rocío Ortiz-López , Augusto Rojas-Martínez , Ana Arana-Guajardo , Mario Alberto Garza-Elizondo , Berenice Carrillo-Haro , Alondra Elizabeh Montoya-Montes
Introduction
Low mannose-binding lectin (MBL) concentrations in serum are due mainly to the presence of three punctual mutations in the coding region of the MBL2 gene. SLE patients, who are homozygous for MBL allele variants, have a significantly greater risk of developing infections. With the purpose of examining the association of MBL locus haplotypes with disease activity and past history of infection in SLE, we studied a group of patients treated in the Rheumatology Outpatient Clinic of the UANL University Hospital.
Objective
Determine the prevalence of MBL2 locus haplotypes and the causal associations between MBL2 locus haplotypes and SLE determining the Hardy–Weinberg law for specific genotypes in both groups of study.
Materials and methods
An observational, cross-sectional, retrospective study was performed. Hardy–Weinberg equilibrium for genotypic frequencies was proven with the X2 test. The risk of lupus associated with MBL2 genotypes as a genetic factor and the strength of the association of the genotypes with the frequency of clinical characteristics was estimated by calculation of odds ratio with a 95% confidence interval. Statistical significance was taken as a value of P < .05.
Results
The findings suggest potential genetic associations between allelic systems and the risk of SLE. A relationship was found regarding the MEX-SLEDAI index, as well as the number of infections among patients with differences in structural gene polymorphisms and promoter gene polymorphisms.
Conclusions
There are significant differences in the polymorphisms of the promoter region regarding the risk for developing SLE.
{"title":"Is there an association between MBL2 gene polymorphisms and infection susceptibility in patients with systemic lupus erythematosus? An exploratory study in Mexican mestizos","authors":"Miguel Ángel Villarreal-Alarcón , Jorge Antonio Esquivel-Valerio , David Vega-Morales , Jorge Armando Hermosillo-Villafranca , Rocío Ortiz-López , Augusto Rojas-Martínez , Ana Arana-Guajardo , Mario Alberto Garza-Elizondo , Berenice Carrillo-Haro , Alondra Elizabeh Montoya-Montes","doi":"10.1016/j.rcreue.2025.09.006","DOIUrl":"10.1016/j.rcreue.2025.09.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Low mannose-binding lectin (MBL) concentrations in serum are due mainly to the presence of three punctual mutations in the coding region of the MBL2 gene. SLE patients, who are homozygous for MBL allele variants, have a significantly greater risk of developing infections. With the purpose of examining the association of MBL locus haplotypes with disease activity and past history of infection in SLE, we studied a group of patients treated in the Rheumatology Outpatient Clinic of the UANL University Hospital.</div></div><div><h3>Objective</h3><div>Determine the prevalence of MBL2 locus haplotypes and the causal associations between MBL2 locus haplotypes and SLE determining the Hardy–Weinberg law for specific genotypes in both groups of study.</div></div><div><h3>Materials and methods</h3><div>An observational, cross-sectional, retrospective study was performed. Hardy–Weinberg equilibrium for genotypic frequencies was proven with the <em>X</em><sup>2</sup> test. The risk of lupus associated with MBL2 genotypes as a genetic factor and the strength of the association of the genotypes with the frequency of clinical characteristics was estimated by calculation of odds ratio with a 95% confidence interval. Statistical significance was taken as a value of <em>P</em> <!--><<!--> <!-->.05.</div></div><div><h3>Results</h3><div>The findings suggest potential genetic associations between allelic systems and the risk of SLE. A relationship was found regarding the MEX-SLEDAI index, as well as the number of infections among patients with differences in structural gene polymorphisms and promoter gene polymorphisms.</div></div><div><h3>Conclusions</h3><div>There are significant differences in the polymorphisms of the promoter region regarding the risk for developing SLE.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 321-327"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.09.003
Rodrigo Lozano-Lozano , Jorge Antonio Esquivel-Valerio , Mitzi Rivera-Beltrán , Oscar Martínez-Díaz , Alondra Elizabeth Montoya-Montes , David Vega-Morales
Introduction/Objectives
The prevalence of falls in RA patients ranges from 14.3% to 54%. Some tools for assessing falls risk predict this in the elderly population. As RA usually begins at a younger age, it would be worth exploring the risk of falls in this age set of patients. Downton index > 3 and a Tinetti scale < 18 are predictive of fall risk. The study aims to determine the association of RA disease activity and health assessment with falls risk.
Materials and methods
Observational, cross-sectional study in RA patients. Demographics, DAS28, HAQ-DI medications, Tinetti scale, and Downton index were obtained.
Results
We included 108 patients, 98 (90.7%) were women. Patients’ mean age was 52.5 ± 10.8 years. Median DAS-28 and HAQ-DI scores were 3.6 and .81. Sixty (55.6%) patients had previous falls. We observed a positive significant correlation between the Downton index and patient's age (rho = .44, p < .001), RA diagnosis time (rho = .23, p = .014), RA activity (DAS-28 score) (rho = .61, p < .001), and a HAQ-DI score (rho = .709, p < .001). Overall, the total Tinetti evaluation scale was significantly correlated with age (rho = −.36, p < .001), time since RA diagnosis (rho = −.20, p = .031), RA activity (DAS-28 score) (rho = −.77, p < .001), and HAQ-DI score (rho = −.835, p < .001). After a multivariate analysis, we found that for a high risk of falls by Downton score, age > 52 years had an OR 7.5 (95% CI, 3.1–17.7; p = .001), a DAS-28 > 3.5 had an OR 9.1 (95% CI, 3.7–22.1; p = .02), and a HAD-QI > .94 had an OR 27.9 (95% CI, 7.1–100.9; p = .001). For a Tinetti score that predicts risk of falls, a HAD-QI > 1.44 had an OR 1.8 (95% CI, 1.28–2.52; p = .001).
Conclusions
There is a correlation between DAS-28 and HAD-QI scores and risk of falls in younger RA patients. The DAS-28 and HAD-QI can predict falls risk using surrogate scales. The risk of falls is an assessment that should be considered RA patients.
RA患者跌倒的发生率为14.3% ~ 54%。一些评估跌倒风险的工具可以预测老年人的这种情况。由于RA通常开始于较年轻的年龄，因此值得探索这个年龄段患者跌倒的风险。唐顿指数（Downton index）和蒂内蒂指数（Tinetti scale）分别为3和18。该研究旨在确定RA疾病活动和健康评估与跌倒风险的关系。材料与方法对RA患者进行观察性横断面研究。统计数据、DAS28、HAQ-DI用药、Tinetti量表、唐顿指数。结果纳入108例患者，其中98例（90.7%）为女性。患者平均年龄52.5±10.8岁。DAS-28和HAQ-DI评分中位数分别为3.6和0.81。60例（55.6%）患者既往有跌倒史。我们观察到唐顿指数与患者年龄（rho = 0.44, p < .001）、RA诊断时间（rho = 0.23, p = 0.014）、RA活动性（DAS-28评分）（rho = 0.61, p < .001）、HAQ-DI评分（rho = 0.709, p < .001）呈正相关。总体而言，总Tinetti评价量表与年龄显著相关（rho =−）。36, p < .001)， RA诊断时间(rho = -。20 p = .031) RA活动(DAS-28分数)(ρ=−。77, p < .001)， HAQ-DI评分(rho = -。835, p < .001)。多因素分析后，我们发现，对于唐顿评分的高风险患者，52岁的OR为7.5 (95% CI, 3.1-17.7; p = .001), DAS-28 >； 3.5的OR为9.1 (95% CI, 3.7-22.1; p = .02), had - qi >； 94的OR为27.9 （95% CI, 7.1-100.9; p = .001）。对于预测跌倒风险的Tinetti评分，had - qi >； 1.44的OR为1.8 （95% CI, 1.28-2.52; p = .001）。结论DAS-28和hd - qi评分与年轻RA患者跌倒风险存在相关性。DAS-28和HAD-QI可以使用替代量表预测跌倒风险。跌倒的风险是一个评估，应该考虑RA患者。
{"title":"Association of disease activity and health assessment with the risk of falls in RA patients: Are DAS-28 and HAQ-DI scores related with the risk of falls assessed in RA patients?","authors":"Rodrigo Lozano-Lozano , Jorge Antonio Esquivel-Valerio , Mitzi Rivera-Beltrán , Oscar Martínez-Díaz , Alondra Elizabeth Montoya-Montes , David Vega-Morales","doi":"10.1016/j.rcreue.2025.09.003","DOIUrl":"10.1016/j.rcreue.2025.09.003","url":null,"abstract":"<div><h3>Introduction/Objectives</h3><div>The prevalence of falls in RA patients ranges from 14.3% to 54%. Some tools for assessing falls risk predict this in the elderly population. As RA usually begins at a younger age, it would be worth exploring the risk of falls in this age set of patients. Downton index<!--> <!-->><!--> <!-->3 and a Tinetti scale<!--> <!--><<!--> <!-->18 are predictive of fall risk. The study aims to determine the association of RA disease activity and health assessment with falls risk.</div></div><div><h3>Materials and methods</h3><div>Observational, cross-sectional study in RA patients. Demographics, DAS28, HAQ-DI medications, Tinetti scale, and Downton index were obtained.</div></div><div><h3>Results</h3><div>We included 108 patients, 98 (90.7%) were women. Patients’ mean age was 52.5<!--> <!-->±<!--> <!-->10.8 years. Median DAS-28 and HAQ-DI scores were 3.6 and .81. Sixty (55.6%) patients had previous falls. We observed a positive significant correlation between the Downton index and patient's age (rho<!--> <!-->=<!--> <!-->.44, <em>p</em> <!--><<!--> <!-->.001), RA diagnosis time (rho<!--> <!-->=<!--> <!-->.23, <em>p</em> <!-->=<!--> <!-->.014), RA activity (DAS-28 score) (rho<!--> <!-->=<!--> <!-->.61, <em>p</em> <!--><<!--> <!-->.001), and a HAQ-DI score (rho<!--> <!-->=<!--> <!-->.709, <em>p</em> <!--><<!--> <!-->.001). Overall, the total Tinetti evaluation scale was significantly correlated with age (rho<!--> <!-->=<!--> <!-->−.36, <em>p</em> <!--><<!--> <!-->.001), time since RA diagnosis (rho<!--> <!-->=<!--> <!-->−.20, <em>p</em> <!-->=<!--> <!-->.031), RA activity (DAS-28 score) (rho<!--> <!-->=<!--> <!-->−.77, <em>p</em> <!--><<!--> <!-->.001), and HAQ-DI score (rho<!--> <!-->=<!--> <!-->−.835, <em>p</em> <!--><<!--> <!-->.001). After a multivariate analysis, we found that for a high risk of falls by Downton score, age<!--> <!-->><!--> <!-->52 years had an OR 7.5 (95% CI, 3.1–17.7; <em>p</em> <!-->=<!--> <!-->.001), a DAS-28<!--> <!-->><!--> <!-->3.5 had an OR 9.1 (95% CI, 3.7–22.1; <em>p</em> <!-->=<!--> <!-->.02), and a HAD-QI<!--> <!-->><!--> <!-->.94 had an OR 27.9 (95% CI, 7.1–100.9; <em>p</em> <!-->=<!--> <!-->.001). For a Tinetti score that predicts risk of falls, a HAD-QI<!--> <!-->><!--> <!-->1.44 had an OR 1.8 (95% CI, 1.28–2.52; <em>p</em> <!-->=<!--> <!-->.001).</div></div><div><h3>Conclusions</h3><div>There is a correlation between DAS-28 and HAD-QI scores and risk of falls in younger RA patients. The DAS-28 and HAD-QI can predict falls risk using surrogate scales. The risk of falls is an assessment that should be considered RA patients.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 359-367"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.06.013
Juan C. Pérez-Correa , Darwin J. Ariza-Rodríguez , María C. Díaz-Jiménez , Daniel G. Fernández-Ávila , Juan M. Gutiérrez , Diego Rosselli
Introduction/Objective
Systemic lupus erythematosus (SLE) entails high direct medical costs, derived from the complexity of diagnosis, treatment, and management of associated complications. In Colombia, there are studies on direct outpatient medical costs, and hospital studies are scarce. The present study describes the direct medical costs derived from hospital care in a high complexity hospital in Bogotá.
Materials and methods
Observational, retrospective, partial economic study. A descriptive analysis of the direct medical costs of caring for hospitalized patients with SLE was performed. The data was obtained by reviewing medical records between January and December 2019; Cost data were taken from the amounts billed by the hospital. Costs in Colombian pesos were expressed in dollars.
Results
Costs of 68 patients and 100 hospitalizations were analysed. The mean age was 39 years ± 12.4. The mean hospital stay was 6.8 days ± 6.1. Total direct medical costs were $267,980 USD with a median per hospitalization of $1,622 USD. Non-surgical procedures represented 64% of the costs ($170,708 USD), drugs 25% ($67,494 USD), medical supplies and procedures 9% ($24,936 USD), and 2% ($4,842 USD) respectively.
Conclusion
Hospitalizations of patients with SLE entail high direct medical costs, which do not differ significantly from hospital costs in other countries. Non-surgical procedures and drugs accounted for the largest share of these costs, followed by supplies and surgical procedures.
{"title":"Cost of hospital care in patients with systemic lupus erythematosus in a high complexity hospital in Colombia","authors":"Juan C. Pérez-Correa , Darwin J. Ariza-Rodríguez , María C. Díaz-Jiménez , Daniel G. Fernández-Ávila , Juan M. Gutiérrez , Diego Rosselli","doi":"10.1016/j.rcreue.2025.06.013","DOIUrl":"10.1016/j.rcreue.2025.06.013","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Systemic lupus erythematosus (SLE) entails high direct medical costs, derived from the complexity of diagnosis, treatment, and management of associated complications. In Colombia, there are studies on direct outpatient medical costs, and hospital studies are scarce. The present study describes the direct medical costs derived from hospital care in a high complexity hospital in Bogotá.</div></div><div><h3>Materials and methods</h3><div>Observational, retrospective, partial economic study. A descriptive analysis of the direct medical costs of caring for hospitalized patients with SLE was performed. The data was obtained by reviewing medical records between January and December 2019; Cost data were taken from the amounts billed by the hospital. Costs in Colombian pesos were expressed in dollars.</div></div><div><h3>Results</h3><div>Costs of 68 patients and 100 hospitalizations were analysed. The mean age was 39 years ± 12.4. The mean hospital stay was 6.8 days ± 6.1. Total direct medical costs were $267,980 USD with a median per hospitalization of $1,622 USD. Non-surgical procedures represented 64% of the costs ($170,708 USD), drugs 25% ($67,494 USD), medical supplies and procedures 9% ($24,936 USD), and 2% ($4,842 USD) respectively.</div></div><div><h3>Conclusion</h3><div>Hospitalizations of patients with SLE entail high direct medical costs, which do not differ significantly from hospital costs in other countries. Non-surgical procedures and drugs accounted for the largest share of these costs, followed by supplies and surgical procedures.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 344-350"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.07.001
Andrea Cabra Sierra, Jorge Lechuga-Ortiz, Yimy Medina Velásquez, Luis Javier Cajas Santana
We present the case of an adult female patient with a diagnosis of IPAF (Interstitial pneumonia with autoimmune features) based on serological and morphological domains according to the diagnostic consensus, in whom the additional positivity of an autoantibody not considered until now within the serological domain is highlighted, namely antineutrophil cytoplasmic antibodies (ANCA)-C. The patient failed multiple treatments. In the medical literature, there is growing interest in defining the usefulness of including ANCA as a significant autoantibody in the diagnosis of IPAF. This is the first case reported in Colombia.
{"title":"Are ANCA antibodies necessary in the definition of interstitial pneumonia with autoimmune features? Illustrative case presentation","authors":"Andrea Cabra Sierra, Jorge Lechuga-Ortiz, Yimy Medina Velásquez, Luis Javier Cajas Santana","doi":"10.1016/j.rcreue.2025.07.001","DOIUrl":"10.1016/j.rcreue.2025.07.001","url":null,"abstract":"<div><div>We present the case of an adult female patient with a diagnosis of IPAF (Interstitial pneumonia with autoimmune features) based on serological and morphological domains according to the diagnostic consensus, in whom the additional positivity of an autoantibody not considered until now within the serological domain is highlighted, namely antineutrophil cytoplasmic antibodies (ANCA)-C. The patient failed multiple treatments. In the medical literature, there is growing interest in defining the usefulness of including ANCA as a significant autoantibody in the diagnosis of IPAF. This is the first case reported in Colombia.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 416-420"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rcreue.2025.06.011
Ana Ospina-Caicedo , Beatriz Eugenia Bastidas Sánchez , Daniel Camilo Bastidas Burbano , Andrea Milena Villota Enríquez , María Fernanda Muñoz Rivera , Cristian Alfonso Campo Guzmán
Introduction
Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease, to which high morbidity and mortality are attributed that affect quality of life.
Objective
To estimate the quality of life of patients hospitalized with systemic lupus erythematosus in a tertiary institution in Colombia.
Materials and methods
Descriptive, observational cross-sectional design of patients with SLE, hospitalized between July 2022 and January 2023, to whom an instrument that included the SF-36 quality of life scale was applied.
Results
Forty-four patients were included, with an average age of 37 years, 88.6% women. The main cause of hospitalization was disease activity at 61.3%. The physical role was the most affected with an average of 23.5 points and 78.9% of the participants had deterioration in physical functioning, especially among women, mixed race, with more than 1 year from diagnosis and independently of the manifestations of the disease. The dimension of health change and social role were especially affected in patients with moderate to high activity, and the use of glucocorticoids was related to this negative impact on health change.
Conclusion
It is necessary to study the quality of life in hospitalized patients with SLE for a comprehensive approach to treatment, taking into account that physical role and functioning are the dimensions most affected globally, and that the health change and social role dimensions are the most affected in those with moderate to high disease activity.
{"title":"Estimation of quality of life in patients hospitalized with systemic lupus erythematosus in a third level institution in Colombia","authors":"Ana Ospina-Caicedo , Beatriz Eugenia Bastidas Sánchez , Daniel Camilo Bastidas Burbano , Andrea Milena Villota Enríquez , María Fernanda Muñoz Rivera , Cristian Alfonso Campo Guzmán","doi":"10.1016/j.rcreue.2025.06.011","DOIUrl":"10.1016/j.rcreue.2025.06.011","url":null,"abstract":"<div><h3>Introduction</h3><div><span>Systemic lupus erythematosus<span> (SLE) is a chronic and systemic autoimmune disease, to which high morbidity and mortality are attributed that affect </span></span>quality of life.</div></div><div><h3>Objective</h3><div>To estimate the quality of life of patients hospitalized with systemic lupus erythematosus in a tertiary institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>Descriptive, observational cross-sectional design of patients with SLE, hospitalized between July 2022 and January 2023, to whom an instrument that included the SF-36 quality of life scale was applied.</div></div><div><h3>Results</h3><div><span>Forty-four patients were included, with an average age of 37 years, 88.6% women. The main cause of hospitalization was disease activity at 61.3%. The physical role was the most affected with an average of 23.5 points and 78.9% of the participants had deterioration in physical functioning, especially among women, mixed race, with more than 1 year from diagnosis and independently of the manifestations of the disease. The dimension of health change and social role were especially affected in patients with moderate to high activity, and the use of </span>glucocorticoids was related to this negative impact on health change.</div></div><div><h3>Conclusion</h3><div>It is necessary to study the quality of life in hospitalized patients with SLE for a comprehensive approach to treatment, taking into account that physical role and functioning are the dimensions most affected globally, and that the health change and social role dimensions are the most affected in those with moderate to high disease activity.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 335-343"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.rcreue.2025.06.004
José Lucas Daza , María Victoria Cabrera , Marcelo de Rosa , Ignacio Roca , Veronica Remache , Juan Sebastián Reyes Bello
Introduction
Primary membranous nephropathy (PMN) poses a therapeutic challenge, necessitating effective treatment approaches. This study aims to assess the response of PMN patients to three treatment strategies: traditional Ponticelli scheme, monthly intravenous cyclophosphamide, and calcineurin inhibitors over a 6–12-month follow-up.
Objective
This study evaluates primary membranous nephropathy (PMN) patients diagnosed by renal biopsy, examining their response to three treatment schemes over a 6–12-month follow-up: traditional Ponticelli scheme, monthly intravenous cyclophosphamide, and calcineurin inhibitors.
Materials and methods
A multicentre retrospective analysis in three Latin American countries (Argentina, Colombia, Bolivia) encompassing 110 PMN patients diagnosed by renal biopsy over 5 years. Excluding 29 with incomplete records or a 12-month follow-up, patients were grouped by treatment: Ponticelli, intravenous cyclophosphamide, and calcineurin inhibitors. Clinical, histological, and laboratory features were compared for complete remission at one year according to KDIGO 2020 guidelines. Univariate and multivariate analyses were conducted. A comparative analysis of remission rates and adverse effects between the oral cyclophosphamide regimen versus calcineurin inhibitors was performed.
Results
Male sex showed the highest prevalence at 60.5%, with an average age of 50.3 ± 14, mainly in stage II (53.1%), and risk distribution (46.9% moderate, 53.1% high). CP IV showed higher haematuria, older age, and lower albuminaemia. While CP IV showed a trend toward higher complete remission (83%) at 12 months compared to CP PO (52%) and CNI (79%), statistical significance (p = .08) was not reached. Complications were significantly lower with CP IV (6.7%) and CNI (4.2%) than with CP PO (41%) with an OR 9.62 and a p-value of .006. These findings underscore the nuanced relationship between treatment modalities, remission rates, and complications in primary membranous nephropathy patients.
Conclusion
The traditional Ponticelli scheme did not significantly differ from intravenous cyclophosphamide and calcineurin inhibitors in achieving complete remission at 6 and 12 months. However, the Ponticelli group exhibited higher cumulative cyclophosphamide doses and more infectious complications compared to other subgroups.
{"title":"Primary membranous nephropathy in Latin America: A multicentre study","authors":"José Lucas Daza , María Victoria Cabrera , Marcelo de Rosa , Ignacio Roca , Veronica Remache , Juan Sebastián Reyes Bello","doi":"10.1016/j.rcreue.2025.06.004","DOIUrl":"10.1016/j.rcreue.2025.06.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Primary membranous nephropathy (PMN) poses a therapeutic challenge, necessitating effective treatment approaches. This study aims to assess the response of PMN patients to three treatment strategies: traditional Ponticelli scheme, monthly intravenous cyclophosphamide, and calcineurin inhibitors over a 6–12-month follow-up.</div></div><div><h3>Objective</h3><div>This study evaluates primary membranous nephropathy (PMN) patients diagnosed by renal biopsy, examining their response to three treatment schemes over a 6–12-month follow-up: traditional Ponticelli scheme, monthly intravenous cyclophosphamide, and calcineurin inhibitors.</div></div><div><h3>Materials and methods</h3><div>A multicentre retrospective analysis in three Latin American countries (Argentina, Colombia, Bolivia) encompassing 110 PMN patients diagnosed by renal biopsy over 5 years. Excluding 29 with incomplete records or a 12-month follow-up, patients were grouped by treatment: Ponticelli, intravenous cyclophosphamide, and calcineurin inhibitors. Clinical, histological, and laboratory features were compared for complete remission at one year according to KDIGO 2020 guidelines. Univariate and multivariate analyses were conducted. A comparative analysis of remission rates and adverse effects between the oral cyclophosphamide regimen versus calcineurin inhibitors was performed.</div></div><div><h3>Results</h3><div>Male sex showed the highest prevalence at 60.5%, with an average age of 50.3<!--> <!-->±<!--> <!-->14, mainly in stage II (53.1%), and risk distribution (46.9% moderate, 53.1% high). CP IV showed higher haematuria, older age, and lower albuminaemia. While CP IV showed a trend toward higher complete remission (83%) at 12 months compared to CP PO (52%) and CNI (79%), statistical significance (<em>p</em> <!-->=<!--> <!-->.08) was not reached. Complications were significantly lower with CP IV (6.7%) and CNI (4.2%) than with CP PO (41%) with an OR 9.62 and a <em>p</em>-value of .006. These findings underscore the nuanced relationship between treatment modalities, remission rates, and complications in primary membranous nephropathy patients.</div></div><div><h3>Conclusion</h3><div>The traditional Ponticelli scheme did not significantly differ from intravenous cyclophosphamide and calcineurin inhibitors in achieving complete remission at 6 and 12 months. However, the Ponticelli group exhibited higher cumulative cyclophosphamide doses and more infectious complications compared to other subgroups.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 3","pages":"Pages 190-197"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.rcreue.2025.03.002
Ana Ospina-Caicedo , Alex Imbachí-Salamanca , Ingris Peláez-Ballestas , María V. Torres-Andrade , Edgar A. Castro-Franco , Jaime Coral-Enríquez , Diana Rodríguez , Jorge Izquierdo-Loaiza
Introduction
Rheumatic diseases are a frequent cause of disability, deterioration in quality of life, and high health costs. The objective of the study was to estimate the prevalence of rheumatic diseases using COPCORD methodology in the Indigenous Misak people of the Guambia - Cauca reservation, over 18 years of age.
Materials and methods
A community-based cross-sectional study was carried out using systematic random sampling, in 3 stages: (1) selection of participants house by house following the main rural road of each village of the Guambia reservation. (2) Application of the COPCORD questionnaire, Spanish version or version adapted and validated to Wam, Misak language), by standardized bilingual interviewers. (3) Confirmation of the diagnosis was made by rheumatologists with access to all the information. Descriptive statistics were performed.
Results
Of a total of 624 people surveyed, 67% were women, the average age was 44 years, 49.2% had basic primary education, and 79.4% spoke Spanish. Pain in the last 7 days and/or history was reported in 366 respondents (58.6%). One hundred and ninety-two patients received medical evaluation, of which 27 (4.33%) had a diagnosis of rheumatic disease and particularly 21 (3.36%) of rheumatoid arthritis.
Conclusion
The prevalence of rheumatic diseases was lower than reported, however the prevalence of rheumatoid arthritis (3.36%) was higher than that reported in the rest of the country and in other Indigenous communities in Latin America. Rheumatic diseases represent a public health problem and specific information on Indigenous groups is necessary for the design of specific interventions.
{"title":"Prevalence of musculoskeletal disorders and rheumatic diseases in a Colombian misak indigenous community: a cross-sectional study using COPCORD methodology","authors":"Ana Ospina-Caicedo , Alex Imbachí-Salamanca , Ingris Peláez-Ballestas , María V. Torres-Andrade , Edgar A. Castro-Franco , Jaime Coral-Enríquez , Diana Rodríguez , Jorge Izquierdo-Loaiza","doi":"10.1016/j.rcreue.2025.03.002","DOIUrl":"10.1016/j.rcreue.2025.03.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatic diseases are a frequent cause of disability, deterioration in quality of life, and high health costs. The objective of the study was to estimate the prevalence of rheumatic diseases using COPCORD methodology in the Indigenous Misak people of the Guambia - Cauca reservation, over 18 years of age.</div></div><div><h3>Materials and methods</h3><div>A community-based cross-sectional study was carried out using systematic random sampling, in 3 stages: (1) selection of participants house by house following the main rural road of each village of the Guambia reservation. (2) Application of the COPCORD questionnaire, Spanish version or version adapted and validated to Wam, Misak language), by standardized bilingual interviewers. (3) Confirmation of the diagnosis was made by rheumatologists with access to all the information. Descriptive statistics were performed.</div></div><div><h3>Results</h3><div>Of a total of 624 people surveyed, 67% were women, the average age was 44 years, 49.2% had basic primary education, and 79.4% spoke Spanish. Pain in the last 7 days and/or history was reported in 366 respondents (58.6%). One hundred and ninety-two patients received medical evaluation, of which 27 (4.33%) had a diagnosis of rheumatic disease and particularly 21 (3.36%) of rheumatoid arthritis.</div></div><div><h3>Conclusion</h3><div>The prevalence of rheumatic diseases was lower than reported, however the prevalence of rheumatoid arthritis (3.36%) was higher than that reported in the rest of the country and in other Indigenous communities in Latin America. Rheumatic diseases represent a public health problem and specific information on Indigenous groups is necessary for the design of specific interventions.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 3","pages":"Pages 198-208"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：